AIP
BNTX icon

Arrowpoint Investment Partners’s BioNTech BNTX Stock Holding History

Arrowpoint Investment Partners’s Portfolio BNTX Stock Details BNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$679K Buy
7,301
+411
+6% +$38.7K 0.15% 67
2026
Q1 		$612K Buy
+6,890
New +$708K 0.54% 36

Other funds holding BNTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Flossbach Von Storch
Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
GP
GSK plc London $602M AUM

Arrowpoint Investment Partners's BNTX Position: Q2 2026 in Review

Arrowpoint Investment Partners increased its BioNTech (BNTX) stake by 6% in Q2 2026, buying an estimated $38.7K and bringing the position to 7,301 shares worth $679K. The position accounts for 0.15% of the portfolio, ranked #67.

Arrowpoint Investment Partners first reported a position in BNTX in Q1 2026 and has held it in 2 quarters since. 283 funds tracked by Wall St. Rank hold BNTX as of Q2 2026.

  • Arrowpoint Investment Partners held 7,301 shares of BioNTech worth $679K as of Q2 2026.
  • Arrowpoint Investment Partners bought 411 BioNTech shares in Q2 2026, an estimated $38.7K.
  • BioNTech made up 0.15% of Arrowpoint Investment Partners's portfolio in Q2 2026, its #67 holding.
  • Arrowpoint Investment Partners first reported a position in BioNTech in Q1 2026 and has held it in 2 quarters since.
  • 283 funds tracked by Wall St. Rank held BioNTech as of Q2 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.